Heart Transplantation

Artificial heart company tries to reassure investors as tests slow down

Published in Heart Disease Weekly, January 19th, 2003

Analysts and investors say Abiomed, Inc., the maker of the first self-contained artificial heart, faces an unusual dilemma: finding patients sick enough to qualify for its tests but healthy enough not to jeopardize the product's reputation by dying too soon.

Abiomed gained worldwide attention in 2001 by implanting 6 of its AbioCor hearts into critically ill patients. But surgeons have tried the procedure just once in 2002, and not at all since ending a moratorium on recruiting 3 months ago.

The slowdown of the trial has dispirited investors. Abiomed shares, which traded at $17 in December 2001, fell below $4 in December 2002.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Heart Disease Weekly

Source: Heart Disease Weekly (2003-01-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry